17 results about "Occlusive disease" patented technology

The present invention provides a laser illumination device for treating a peripheral artery occlusive disease, which comprises: a fixing frame, which includes a fixing member and a bracket, the fixing member is disposed on the top of the bracket, and the inner side of the fixing member is disposed with a plurality of a first laser diodes which are used to emit laser light with a wavelength between 620 and 700 nm, and a plurality of a second laser diodes which are used to emit laser light with a wavelength between 900 and 1100 nm; a power source, which is disposed on the fixing frame and is used to supply power to the plurality of laser diodes; and a tripod, which is disposed at the bottom of the bracket to support the fixing frame.

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis, and chronic obstructive pulmonary disorder (COPD).

The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; R2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R3, R4, R5, R6, R7 and R8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R2, R3, R4 is H; X1, X2, X3, X4, X5 and X6 are independently N or C; with the proviso that in each ring maximal one X is N.

The invention discloses a pharmaceutical composition for treating cardiovascular blockage diseases and cognitive impairment and new application thereof.The pharmaceutical composition is a traditional Chinese medicine compound heart-tonifying and mental-tranquilizing formula, and the compound has the effects of tonifying qi, activating blood, dispersing blood stasis, replenishing essence, nourishing yin and the like; the traditional Chinese medicine composition can be used for integrally intervening a plurality of pathological links of cardiovascular blockage diseases such as myocardial infarction and cognitive impairment diseases such as Alzheimer's disease, not only can improve the functions of the heart and the brain, but also can obviously improve the life quality of a patient, achieves a good clinical curative effect, and does not have obvious adverse reaction.

The present application relates to the technical field of medicine, and discloses application of gastrodin in preparation of medicine for preventing and treating radioactive liver injury, wherein the radioactive liver injury is liver injury caused by ionizing radiation exposure. It is found that the gastrodin can effectively intervene in specific mechanism of the radioactive liver injury, significantly reduce the mortality of the radioactive liver injury mice, reverse the hepatic veno-occlusive disease and the core pathological features of liver fibrosis of the radioactive liver injury, and more specifically treat the radioactive liver injury. On the other hand, the gastrodin can be used before radiation exposure to prevent serious radioactive liver injury after radiation exposure.

The invention is applicable to the technical field of gene detection, and provides a gene marker, a primer, a probe and a kit for predicting a child graft versus host disease and application of the gene marker, the primer, the probe and the kit. It is found for the first time that a combination of 12 gene markers including TPMT, UGT2B10, BHLHE22, KIAA1715, GSTA1, GSTM1, CTH, MTHFR, CYP2B6, HFE, CPS and HPSE in peripheral blood of a child patient suffering from the graft versus host disease and the hepatic minor vein occlusion disease has significant difference between hematopoietic stem cell transplanted child patients suffering from the GVHD and hematopoietic stem cell transplanted child patients not suffering from the GVHD, the combination can be used as one of laboratory immunity related detection indexes for auxiliary diagnosis of the GVHD, operation is easy and feasible, and the method is suitable for clinical application. The clinical application value is very high. According to the kit for predicting the child graft versus host disease, 17 SNP loci and one genotype homozygous deletion are detected, genetic typing is completed by combining a high-throughput sequencing and capillary electrophoresis combined method, risk assessment can be further given according to the typing result of a patient, and individualized susceptible gene detection is achieved.

An integrated multifunctional vascular intervention catheter sheath belongs to the technical field of medical equipment and comprises a sheath tube body and a balloon, a cavity tube is arranged in the sheath tube body, and a mounting cavity is arranged between the outer side of the cavity tube and the inner side of the sheath tube body; a guide tube is arranged on one side of the upper end of the sheathing canal body, a camera catheter, an illuminating lamp catheter, a saline flushing catheter and a standby catheter are installed in the installation cavity, a balloon control tube is installed on the other side of the sheathing canal body, and a fixing hole in the lower side of a balloon is fixedly formed in the outer side of the sheathing canal body. The balloon upper side fixing hole is fixedly formed in the outer side of the lower end of the sheath tube body and the balloon control tube. The medical balloon can be used in cooperation with a camera, a lighting lamp, a washing device, a suction device and other devices, the functions of imaging in a blood vessel cavity, removing blood flow interference, spraying medicine and sucking out contents can be achieved, lesion fragments and sprayed medicine generated in the opening process of arterial occlusion disease blood vessels and the like can be removed in time, and the balloon can expand narrow blood vessels or block operation openings; and the technical support is provided for the vascular interventional operation.

The present invention relates to compounds of formula (I) as inhibitors of mannan-binding lectin-associated serine protease-2 (MASP-2), including inhibitors that selectively inhibit MASP-2 over thrombin, for use in the treatment of e.g. a thrombotic microangiopathy (TMA), a renal condition, an inflammatory reaction resulting from tissue or organ transplantation, an ischemia reperfusion injury, a complication associated with diabetes, a cardiovascular disease or disorder, an inflammatory gastrointestinal disorder, a pulmonary disorder, an ophthalmic disease or disorder, disseminated intravascular coagulation, graft-versus-host disease, veno-occlusive disease, diffuse alveolar hemorrhage, idiopathic pneumonia syndrome, capillary leak syndrome, engraftment syndrome, fluid overload, a traumatic brain injury (TBI) or a combination thereof

The present invention provides a prodrug of treprostinil as shown in formula I and a pharmaceutical composition thereof, wherein the prodrug can specifically bind to prostaglandin receptors, relax vascular smooth muscle, and can be used to treat pulmonary hypertension, chronic arterial occlusive disease, idiopathic pulmonary fibrosis and other diseases. The prodrug also optimizes the pharmacokinetic characteristics of treprostinil and the irritation of the drug, reduces the dosage and frequency of administration, and improves the effectiveness and safety of the drug.

The application discloses a kind of drug composition for treating cardiovascular occlusion diseases and cognitive impairment and its new purposes, and the drug composition is traditional Chinese medicine compound Yixin Yangshen formula, the comprehensive effect of the compound, such as invigorating qi, promoting blood circulation, removing blood stasis, filling essence, nourishing yin, etc., can be used for the whole intervention of multiple pathological links of cardiovascular occlusion diseases such as myocardial infarction and cognitive impairment diseases such as Alzheimer's disease, not only can improve the function of heart and brain, but also can significantly improve the quality of life of patients, and good clinical efficacy is obtained, and no obvious adverse reactions occur.

The invention relates to the technical field of medicines, and discloses application of gastrodin in preparation of a medicine for preventing and treating radioactive liver injury, and the radioactive liver injury is liver injury caused by ionizing radiation exposure. The gastrodin is found to be capable of effectively intervening a specific mechanism of the radiation-induced liver injury, so that the death rate of mice with the radiation-induced liver injury is remarkably reduced, meanwhile, the core pathological characteristics of hepatic vein occlusion and hepatic fibrosis of the radiation-induced liver injury are reversed, and the radiation-induced liver injury is treated in a more targeted manner. On the other hand, gastrodin is used before radiation exposure, so that serious radioactive liver injury after radiation exposure can be prevented.

The utility model provides a laser irradiation device for treating peripheral artery occlusion diseases, which comprises a fixing frame, the fixing frame comprises a fixing component and a support, the fixing component is arranged at the top of the support, a plurality of first laser diodes are arranged on the inner side of the fixing component and used for emitting laser with the wavelength ranging from 620 nm to 700 nm, and the first laser diodes are used for emitting laser with the wavelength ranging from 620 nm to 700nm; the second laser diodes are used for emitting laser with the wavelength ranging from 900 nm to 1100 nm; the power supply is arranged on the fixed frame and is used for supplying power to the plurality of laser diodes; the foot stool is arranged at the bottom of the bracket and is used for supporting the fixing frame; wherein the plurality of laser diodes are used for emitting laser light of different wavelengths to irradiate an affected part of a patient suffering from the peripheral artery occlusion disease.

In one aspect, the invention provides a method of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from graft-versus-host disease and / or diffuse alveolar hemorrhage and / or veno-occlusive disease associated with hematopoietic stem cell transplantation. The method comprises the step of administering to a subject in need thereof an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

An object of the present invention is to provide a compound having a PDGF receptor kinase inhibitory activity.Examples of the present invention may include, for example, a compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof.The compound of the present invention has an inhibitory activity against the PDGF receptor kinase. In addition, since the compound of the present invention has an inhibitory activity against the PDGF receptor kinase, it is useful as a therapeutic agent for respiratory diseases, cancers, smooth muscle proliferative diseases, vasoproliferative diseases, autoimmune / inflammatory diseases, metabolic diseases, vasoocclusive diseases, and the like.

The present invention relates to compounds of formula (I) as inhibitors of mannan-binding lectin-associated serine protease-2 (MASP-2), including inhibitors that selectively inhibit MASP-2 over thrombin, for use in the treatment of e.g. a thrombotic microangiopathy (TMA), a renal condition, an inflammatory reaction resulting from tissue or organ transplantation, an ischemia reperfusion injury, a complication associated with diabetes, a cardiovascular disease or disorder, an inflammatory gastrointestinal disorder, a pulmonary disorder, an ophthalmic disease or disorder, disseminated intravascular coagulation, graft-versus-host disease, veno-occlusive disease, diffuse alveolar hemorrhage, idiopathic pneumonia syndrome, capillary leak syndrome, engraftment syndrome, fluid overload, a traumatic brain injury (TBI) or a combination thereof

The utility model relates to a kind of vein stents with high compliance, distal end braided stent is formed by wire with coating weaving, with high compliance, stent expanded diameter is slightly larger than target vein pipe diameter but smaller than proximal end laser engraved stent;Distal end braided stent includes wire, and coating located outside wire, coating is divided into inside coating and outside coating, inside coating curvature ratio is greater than outside coating, the surface roughness of inside coating is smaller than outside coating;A group of metal connecting short rod is connected by welding proximal end laser engraved stent and braided stent two parts.This stent has different structure and mechanical characteristics in different anatomical and kinematic characteristics vein segments, better adaptability, can better meet the needs of non-thrombotic iliofemoral vein stenosis occlusive disease patient iliofemoral vein stent implantation in stent fixation, cross joint placement stent.

Z maps combined with a standardized stimulus in the form of a targeted arterial partial pressures of carbon dioxide provide surprisingly enhanced images for the assessment of pathological CVR. For example, the z-map assessment of patients with known steno-occlusive diseases of the cervico-cerebral vasculature showed an enhanced resolution of the presence, localization, and severity of the pathological CVR. Z-map have been found to be useful to reduce the confounding effects of test-to-test, subject-to-subject, and platform-to-platform variability for comparison of CVR images showing the importance of combining this analysis with the standardized stimulus.